Among these, SMAD4 mutations, present in >50% of cases, represent a critical transition in tumor progression and are associated with increased invasiveness and poor outcomes (Fei et al., 2021; Principe et al., 2022), yet their detailed molecular mechanisms remain poorly understood. This evidence concerns the gene SMAD4 and neoplasm.